• small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

2017 News Releases

Webcast ImageWebcast
Q4 2016 MIMEDX GROUP INC Earnings Conference Call (Replay)
Feb 23, 2017 at 10:30 a.m. ET
Q4 2016 MIMEDX GROUP INC Earnings Conference Call
Thursday, February 23, 2017 10:30 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
Feb 23, 2017MiMedx Announces 2016 Record Results
MARIETTA, Ga., Feb. 23, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, today announced its record results for the fourth quarter and full year ended December 31, 2016. Full Year 2016 Highlights are: Revenue is a ... 
Printer Friendly Version
Feb 16, 2017MiMedx Announces Release Date for 2016 Full Year Results
MARIETTA, Ga., Feb. 16, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that its results for the fourth quarter and year ended December 31, 2016, will be released before the opening of the market on Thursd... 
Printer Friendly Version
Feb 07, 2017Benefits Of MiMedx dHACM Allograft Chronicled In Multiple Articles In February 2017 Supplement Edition Of Annals of Plastic Surgery
ARTICLES BY RENOWNED PHYSICIANS DEMONSTRATE THE CLINICAL BENEFITS OF dHACM ALLOGRAFTS IN BURN MANAGEMENT AND THE TREATMENT OF DIFFICULT TO HEAL WOUNDS MARIETTA, Ga., Feb. 7, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human placental tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthc... 
Printer Friendly Version
Feb 06, 2017MiMedx Board of Directors Authorizes $10 Million Increase to the Company's Share Repurchase Program
MARIETTA, Ga., Feb. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the decision of its Board of Directors to authorize an increase in the Company's Share Repurchase Program. This action by the MiMe... 
Printer Friendly Version
Feb 03, 2017MiMedx Comments On FDA Decision Not To Finalize HCT/P Guidance Documents This Year
MARIETTA, Ga., Feb. 3, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, commented today regarding the Food and Drug Administration's ("FDA's") recently published 2017 calendar year guidance agenda. The tissue-related Guida... 
Printer Friendly Version
Jan 24, 2017Scientific Study Confirms MiMedx dHACM Allograft Promotes Cardiac Repair Following Myocardial Infarction
STUDY DEMONSTRATES THAT dHACM TREATMENT EFFECTS IMPROVED CELL SURVIVAL, ENHANCED VASCULARIZATION, AND RECRUITMENT OF AUTOLOGOUS STEM CELLS WITHIN INFARCTED CARDIAC TISSUE MARIETTA, Ga., Jan. 24, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Denta... 
Printer Friendly Version
Jan 09, 2017MiMedx Fourth Quarter 2016 Revenue in Upper Range of Guidance
$246.8 Million Full Year 2016 Revenue is a 32% Increase Over 2015 and $71.6 Million Q4 2016 Revenue is a 38% Increase Over Q4 2015 MARIETTA, Ga., Jan. 9, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, today announced ... 
Printer Friendly Version
Jan 03, 2017MiMedx to Present at 35th Annual J.P. Morgan Healthcare Conference
MARIETTA, Ga., Jan. 3, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today the schedule for its presentation at the 35th Annual J.P. Morgan Healthcare Conference.  Parker H. "Pete" Petit, Chairman and CEO, Wil... 
Printer Friendly Version

Products

CONTACT US

888.543.1917